pegylated


Also found in: Dictionary, Wikipedia.

pegylated

(peg'i-lāt-ed),
Substance with chemically attached glycol moieties.
[PEG (polyethylene glycol) + -yl, chemical suffix, + -ated, pp. suffix]

pegylated

or

PEGylated

(pĕg′ə-lā′tĭd)
adj.
Covalently attached to polyethylene glycol, as in certain drugs.
References in periodicals archive ?
A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors (Abstract #3017)
presented interim results from EUROP (Evaluation of Pegylated Interferon (Unipeg(r)) for Response in Pakistani Population) Clinical Trial Study last year at EASL Prague, Czech Republic, September 14-16, 2012.
Loss of the hepatitis B e antigen (HBeAg) and hepatitis B viral (HBV) DNA levels below 200 IU / mL after 48 weeks of therapy occurred in 18% of patients randomized to entecavir (Baraclude) and pegylated interferon alfa-2a (Pegasys), vs.
In Step 3, people who did have an EVR at week 12 took pegylated interferon plus weight-based ribavirin for another 60 weeks.
2] of pegylated liposomal doxorubicin by 90-minute infusion every 4 weeks and 337 women to the combination regimen: a 90-minute infusion of 30 mg/[m.
Patients for the Phase IIb study will be selected based on having genotype 1 chronic HCV and having failed to respond to pegylated alpha interferon plus ribavirin therapy (non-responders).
PEGASYS is a pegylated interferon agent that treats chronic hepatitis C infection with a once-a-week dosage.
A sustained virologic response to hepatitis C treatment is more likely among people who are able to adhere to at least 80% of their full doses of ribavirin and pegylated interferon for at least 80% of the entire duration of therapy.
41% of the non-responder patients tested HCV RNA negative and 50% showed a virologic response after 24 weeks of a new triple therapy of ZADAXIN in combination with pegylated interferon alpha and ribavirin.
Combination therapy with pegylated interferon alfa-2a (Pegasys) and the oral antiviral medication ribavirin is being touted as an alternative to standard treatment for Hepatitis C, according to findings released at the May Digestive Disease Week 2001 conference in Atlanta.
The patent, issued October 17, 2000, is based on early pioneering work by PolyMASC inventors and is directed towards PEGylated liposomes (liposomes having polyethylene glycol (PEG) chains attached).